Prime Medicine, Inc.
PRME
$3.70
$0.1454.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 8.35% | 1.22% | 1.14% | -27.64% | -44.56% |
| Total Depreciation and Amortization | 28.17% | 32.49% | 31.70% | 32.32% | 45.36% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -0.64% | 41.23% | 40.88% | 31.25% | 65.86% |
| Change in Net Operating Assets | 426.64% | 384.03% | 1,074.01% | 68.64% | -6.71% |
| Cash from Operations | 49.07% | 45.70% | 25.72% | -20.17% | -37.04% |
| Capital Expenditure | 21.31% | 18.31% | 16.39% | 37.23% | 33.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 443.87% | 1,819.81% | 176.11% | 380.23% | -1,218.38% |
| Cash from Investing | 301.42% | 1,120.99% | 265.86% | 269.57% | -121.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -70.91% | -71.04% | 26,018.47% | -7.89% | -28.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -75.81% | -75.81% | -- | 1,871.43% | 1,255.64% |
| Cash from Financing | -71.68% | -71.79% | 29,804.73% | 6.25% | -13.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 97.54% | 95.63% | 196.87% | 1,970.21% | -329.29% |